Projet d'Arrêté relatif aux méthodes et techniques de contrôle de la conformité des produits primaires, des produits alimentaires et des aliments pour animaux à l'importation (Draft Order on conformity control methods and techniques for imported primary products, food products and animal feed)
Distribution date: 09 February 2016 | Final date for Comment: 04 May 2025
The notified text establishes the conformity control methods and techniques to be employed at the borders on imported primary products, food products and animal feed. Controls on imported goods must be performed prior to customs clearance on the basis of documents submitted by the importer or his authorized representative. Border controls on imported goods involve: 1) documentation checks; 2) identity checks; and 3) physical checks. The notified text details the control procedures. Where goods are refused clearance, the importer or his duly authorized representative may submit a reasoned appeal within eight days of the date of notification of refusal of clearance. The importer or his representative may remove the goods before obtaining the results of the analyses. The importer is responsible for storing the goods, secured by an official customs seal, at premises approved by the National Office for Food Safety (ONSSA) while awaiting the results of the analyses.
Products Covered: Live animals and animal products, plants and plant products and all food products and animal feed, additives, agricultural inputs, pesticides, and veterinary drugs and products.
Regulation Type: Regular notification
<p><span style="text-decoration:underline;">Notice of Intent to Amend the Prescription Drug List (PDL): Ibuprofen</span><br /><br />The proposed amendment notified in G/TBT/N/CAN/469 (dated 2 October 2015) was adopted 5 February 2016.<br /><br />The purpose of this Notice of Intent to Amend is to notify that, as a result of consultation, Health Canada will switch certain uses of Ibuprofen to nonprescription status for human use by modifying the Human Prescription Drug List (PDL). The Veterinary List will remain unchanged. Health Canada has conducted a scientific review of Ibuprofen against the set of established and publicly available criteria outlined in section C.01.040.3 of the Food and Drug Regulations. The wording has not changed from what was proposed in the 2 October 2015 Notice of Consultation.<br /><br />This revision will be in effect six months from the date of this Notice posted on the Health Canada website.<br /><br />The full text of the adopted measure can be downloaded from the Internet addresses indicated below:<br />http://www.hc-sc.gc.ca/dhp-mps/prodpharma/pdl-ord/pdl-ldo-noa-ad-ibuprofen-eng.php (English)<br />http://www.hc-sc.gc.ca/dhp-mps/prodpharma/pdl-ord/pdl-ldo-noa-ad-ibuprofen-fra.php (French)<br /></p><p>or requested from:</p>Canada's Notification Authority and Enquiry Point<br />Global Affairs Canada<br />Technical Barriers and Regulations Division (TIB)<br />111 Sussex Drive<br />Ottawa, ON K1A 0G2<br />Canada<br />Telephone: (343) 203-4273<br />Fax: (613) 943-0346<br />Email: <a href="mailto:[email protected]">[email protected]</a>
Distribution date: 10 February 2016 | Final date for Comment: 04 May 2025
Products Covered: Prescription status of medicinal ingredients for human use (ICS: 11.120; HS 3004.90)
Regulation Type: Addendum to Regular Notification
<p><span style="text-decoration:underline;">Notice of Intent to Amend the Prescription Drug List (PDL): Ibuprofen</span><br /><br />The proposed amendment notified in G/TBT/N/CAN/469 (dated 2 October 2015) was adopted 5 February 2016.<br /><br />The purpose of this Notice of Intent to Amend is to notify that, as a result of consultation, Health Canada will switch certain uses of Ibuprofen to nonprescription status for human use by modifying the Human Prescription Drug List (PDL). The Veterinary List will remain unchanged. Health Canada has conducted a scientific review of Ibuprofen against the set of established and publicly available criteria outlined in section C.01.040.3 of the Food and Drug Regulations. The wording has not changed from what was proposed in the 2 October 2015 Notice of Consultation.<br /><br />This revision will be in effect six months from the date of this Notice posted on the Health Canada website.<br /><br />The full text of the adopted measure can be downloaded from the Internet addresses indicated below:<br />http://www.hc-sc.gc.ca/dhp-mps/prodpharma/pdl-ord/pdl-ldo-noa-ad-ibuprofen-eng.php (English)<br />http://www.hc-sc.gc.ca/dhp-mps/prodpharma/pdl-ord/pdl-ldo-noa-ad-ibuprofen-fra.php (French)<br /></p><p>or requested from:</p>Canada's Notification Authority and Enquiry Point<br />Global Affairs Canada<br />Technical Barriers and Regulations Division (TIB)<br />111 Sussex Drive<br />Ottawa, ON K1A 0G2<br />Canada<br />Telephone: (343) 203-4273<br />Fax: (613) 943-0346<br />Email: <a href="mailto:[email protected]">[email protected]</a>
Distribution date: 10 February 2016 | Final date for Comment: 04 May 2025
Products Covered: Prescription status of medicinal ingredients for human use (ICS: 11.120; HS 3004.90)
Regulation Type: Addendum to Regular Notification
<p>Notice of Intent to Amend the Prescription Drug List (PDL): Esomeprazole</p><p>The proposed amendment notified in G/TBT/N/CAN/468 (dated 2 October 2015) was adopted on 4 February 2016.</p><p>The purpose of this Notice of Intent to Amend is to notify that, as a result of consultation, Health Canada will switch certain uses of Esomeprazole to nonprescription status for human use by modifying the Human Prescription Drug List (PDL). The Veterinary List will remain unchanged. Health Canada has conducted a scientific review of Esomeprazole against the set of established and publicly available criteria outlined in section C.01.040.3 of the Food and Drug Regulations. The wording, which has not changed from what was proposed in the 2 October 2015 Notice of Consultation. </p><p>This revision will be in effect six months from the date of this Notice posted on the Health Canada website.</p><p>The full text of the adopted measure can be downloaded from the Internet addresses indicated below:<br /><a href="http://www.hc-sc.gc.ca/dhp-mps/prodpharma/pdl-ord/pdl-ldo-noa-ad-esomeprazole-eng.php">http://www.hc-sc.gc.ca/dhp-mps/prodpharma/pdl-ord/pdl-ldo-noa-ad-esomeprazole-eng.php</a> (English)<br /><a href="http://www.hc-sc.gc.ca/dhp-mps/prodpharma/pdl-ord/pdl-ldo-noa-ad-esomeprazole-fra.php">http://www.hc-sc.gc.ca/dhp-mps/prodpharma/pdl-ord/pdl-ldo-noa-ad-esomeprazole-fra.php</a> (French)</p><p>or requested from:</p><p>Canada's Notification Authority and Enquiry Point<br />Global Affairs Canada<br />Technical Barriers and Regulations Division (TIB)<br />111 Sussex Drive<br />Ottawa, ON K1A 0G2<br />Canada<br />Telephone: (343) 203-4273<br />Fax: (613) 943-0346<br />Email: <a href="mailto:[email protected]">[email protected]</a> </p>
Distribution date: 10 February 2016 | Final date for Comment: 04 May 2025
Products Covered: Prescription status of medicinal ingredients for human use (ICS: 11.120; HS 3004.90)
Regulation Type: Addendum to Regular Notification
<p>Notice of Intent to Amend the Prescription Drug List (PDL): Esomeprazole</p><p>The proposed amendment notified in G/TBT/N/CAN/468 (dated 2 October 2015) was adopted on 4 February 2016.</p><p>The purpose of this Notice of Intent to Amend is to notify that, as a result of consultation, Health Canada will switch certain uses of Esomeprazole to nonprescription status for human use by modifying the Human Prescription Drug List (PDL). The Veterinary List will remain unchanged. Health Canada has conducted a scientific review of Esomeprazole against the set of established and publicly available criteria outlined in section C.01.040.3 of the Food and Drug Regulations. The wording, which has not changed from what was proposed in the 2 October 2015 Notice of Consultation. </p><p>This revision will be in effect six months from the date of this Notice posted on the Health Canada website.</p><p>The full text of the adopted measure can be downloaded from the Internet addresses indicated below:<br /><a href="http://www.hc-sc.gc.ca/dhp-mps/prodpharma/pdl-ord/pdl-ldo-noa-ad-esomeprazole-eng.php">http://www.hc-sc.gc.ca/dhp-mps/prodpharma/pdl-ord/pdl-ldo-noa-ad-esomeprazole-eng.php</a> (English)<br /><a href="http://www.hc-sc.gc.ca/dhp-mps/prodpharma/pdl-ord/pdl-ldo-noa-ad-esomeprazole-fra.php">http://www.hc-sc.gc.ca/dhp-mps/prodpharma/pdl-ord/pdl-ldo-noa-ad-esomeprazole-fra.php</a> (French)</p><p>or requested from:</p><p>Canada's Notification Authority and Enquiry Point<br />Global Affairs Canada<br />Technical Barriers and Regulations Division (TIB)<br />111 Sussex Drive<br />Ottawa, ON K1A 0G2<br />Canada<br />Telephone: (343) 203-4273<br />Fax: (613) 943-0346<br />Email: <a href="mailto:[email protected]">[email protected]</a> </p>
Distribution date: 10 February 2016 | Final date for Comment: 04 May 2025
Products Covered: Prescription status of medicinal ingredients for human use (ICS: 11.120; HS 3004.90)
Regulation Type: Addendum to Regular Notification
Notification of the Ministry of Industry No. ... (B.E. 25xx) Issued under the Industrial Product Standards Act B.E. 2511(1968): Amending to Thai Industrial Standard for Steel Bars for Reinforced Concrete: Deformed Bar (Amendment No. 1) (4 pages, in Thai)
Distribution date: 16 February 2016 | Final date for Comment: 16 April 2016
<p style="margin:6pt 0cm;text-align:justify;-ms-text-justify:inter-cluster;"><span style="color:black;font-size:x-small;font-face:Verdana;"><span style="color:windowtext;letter-spacing:-0.1pt;font-family:'Verdana','sans-serif';font-size:9pt;">The Thai Industrial Standards Institute (TISI) has proposed to amend the Thai Industrial Standard for </span></span><span style="color:black;font-size:x-small;font-face:Verdana;"><span style="background:white;color:windowtext;font-family:'Verdana','sans-serif';font-size:9pt;">Steel Bars for Reinforced Concrete: Deformed Bar (TIS 24-2548(2005))</span></span><span style="color:black;font-size:x-small;font-face:Verdana;"><span style="color:windowtext;letter-spacing:-0.1pt;font-family:'Verdana','sans-serif';font-size:9pt;">. </span></span><span style="font-size:x-small;font-face:Verdana;"><span lang="EN-GB" style="letter-spacing:-0.1pt;font-family:'Verdana','sans-serif';font-size:9pt;">The main amendment includes raw materials, manufacturing, chemical composition by ladle analysis, chemical composition by product analysis and tolerances and marking.</span></span></p>
Products Covered: Steel bars (HS:7214, ICS: 77.140.60)
Regulation Type: Revision to Regular Notification
Notification of the Ministry of Industry No. ... (B.E. 25xx) Issued under the Industrial Product Standards Act B.E. 2511(1968): Amending to Thai Industrial Standard for Steel Bars for Reinforced Concrete: Deformed Bar (Amendment No. 1) (4 pages, in Thai)
Distribution date: 16 February 2016 | Final date for Comment: 16 April 2016
<p style="margin:6pt 0cm;text-align:justify;-ms-text-justify:inter-cluster;"><span style="color:black;font-size:x-small;font-face:Verdana;"><span style="color:windowtext;letter-spacing:-0.1pt;font-family:'Verdana','sans-serif';font-size:9pt;">The Thai Industrial Standards Institute (TISI) has proposed to amend the Thai Industrial Standard for </span></span><span style="color:black;font-size:x-small;font-face:Verdana;"><span style="background:white;color:windowtext;font-family:'Verdana','sans-serif';font-size:9pt;">Steel Bars for Reinforced Concrete: Deformed Bar (TIS 24-2548(2005))</span></span><span style="color:black;font-size:x-small;font-face:Verdana;"><span style="color:windowtext;letter-spacing:-0.1pt;font-family:'Verdana','sans-serif';font-size:9pt;">. </span></span><span style="font-size:x-small;font-face:Verdana;"><span lang="EN-GB" style="letter-spacing:-0.1pt;font-family:'Verdana','sans-serif';font-size:9pt;">The main amendment includes raw materials, manufacturing, chemical composition by ladle analysis, chemical composition by product analysis and tolerances and marking.</span></span></p>
Products Covered: Steel bars (HS:7214, ICS: 77.140.60)
Regulation Type: Revision to Regular Notification
Notification of the Ministry of Industry No. (B.E. 25xx) Issued under the Industrial Product Standards Act B.E. 2511(1968): Amending to Thai Industrial Standard for Steel Bars for Reinforced Concrete: Round Bar (Amendment No. 1) (3 pages, in Thai)
Distribution date: 16 February 2016 | Final date for Comment: 16 April 2016
<p style="margin:6pt 0cm;text-align:justify;-ms-text-justify:inter-cluster;"><span style="color:black;font-size:x-small;font-face:Verdana;"><span style="color:windowtext;letter-spacing:-0.1pt;font-family:'Verdana','sans-serif';font-size:9pt;">The Thai Industrial Standards Institute (TISI) has proposed to amend the Thai Industrial Standard for </span></span><span style="color:black;font-size:x-small;font-face:Verdana;"><span style="background:white;color:windowtext;font-family:'Verdana','sans-serif';font-size:9pt;">Steel Bars for Reinforced Concrete: Round Bar (TIS 20-2543(2000))</span></span><span style="color:black;font-size:x-small;font-face:Verdana;"><span style="color:windowtext;letter-spacing:-0.1pt;font-family:'Verdana','sans-serif';font-size:9pt;">. </span></span><span style="font-size:x-small;font-face:Verdana;"><span lang="EN-GB" style="letter-spacing:-0.1pt;font-family:'Verdana','sans-serif';font-size:9pt;">The main amendment includes raw materials, manufacturing, chemical composition by ladle analysis and product analysis and marking.</span></span></p>
Products Covered: Steel Bars (HS:7214, ICS: 77.140.60)
Regulation Type: Revision to Regular Notification
Notification of the Ministry of Industry No. (B.E. 25xx) Issued under the Industrial Product Standards Act B.E. 2511(1968): Amending to Thai Industrial Standard for Steel Bars for Reinforced Concrete: Round Bar (Amendment No. 1) (3 pages, in Thai)
Distribution date: 16 February 2016 | Final date for Comment: 16 April 2016
<p style="margin:6pt 0cm;text-align:justify;-ms-text-justify:inter-cluster;"><span style="color:black;font-size:x-small;font-face:Verdana;"><span style="color:windowtext;letter-spacing:-0.1pt;font-family:'Verdana','sans-serif';font-size:9pt;">The Thai Industrial Standards Institute (TISI) has proposed to amend the Thai Industrial Standard for </span></span><span style="color:black;font-size:x-small;font-face:Verdana;"><span style="background:white;color:windowtext;font-family:'Verdana','sans-serif';font-size:9pt;">Steel Bars for Reinforced Concrete: Round Bar (TIS 20-2543(2000))</span></span><span style="color:black;font-size:x-small;font-face:Verdana;"><span style="color:windowtext;letter-spacing:-0.1pt;font-family:'Verdana','sans-serif';font-size:9pt;">. </span></span><span style="font-size:x-small;font-face:Verdana;"><span lang="EN-GB" style="letter-spacing:-0.1pt;font-family:'Verdana','sans-serif';font-size:9pt;">The main amendment includes raw materials, manufacturing, chemical composition by ladle analysis and product analysis and marking.</span></span></p>
Products Covered: Steel Bars (HS:7214, ICS: 77.140.60)
Regulation Type: Revision to Regular Notification
<p><span style="text-decoration:underline;">Notice of Intent to Amend the Prescription Drug List (PDL): Hyoscine butylbromide</span><br /><br />The proposed amendment notified in G/TBT/N/CAN/471 (dated 29 October 2015) was adopted on 12 February 2016.<br /><br />The purpose of this Notice of Intent to Amend is to notify that, as a result of consultation, Health Canada will switch injectable Hyoscine butylbromide to prescription status from ethical status for human use by adding it to the Human Prescription Drug List (PDL). Injectable Hyoscine butylbromide is already listed on the Veterinary Prescription Drug List. Health Canada has conducted a scientific review of Hyoscine butylbromide against the set of established and publicly available criteria outlined in section C.01.040.3 of the Food and Drug Regulations. The wording has not changed from what was proposed in the 16 October 2015 Notice of Consultation.<br />This revision will be in effect six months from the date of this Notice posted on the Health Canada website.<br /><br />The full text of the adopted measure can be downloaded from the Internet addresses indicated below:</p><p><a href="http://www.hc-sc.gc.ca/dhp-mps/prodpharma/pdl-ord/pdl-ldo-noa-ad-hyoscine-butylbromide-eng.php">http://www.hc-sc.gc.ca/dhp-mps/prodpharma/pdl-ord/pdl-ldo-noa-ad-hyoscine-butylbromide-eng.php</a> (English)<br /><a href="http://www.hc-sc.gc.ca/dhp-mps/prodpharma/pdl-ord/pdl-ldo-noa-ad-hyoscine-butylbromide-fra.php">http://www.hc-sc.gc.ca/dhp-mps/prodpharma/pdl-ord/pdl-ldo-noa-ad-hyoscine-butylbromide-fra.php</a> (French)<br /></p><p>or requested from:</p>Canada's SPS & TBT Notification Authority and Enquiry Point<br />Global Affairs Canada<br />Technical Barriers and Regulations Division (TPB)<br />111 Sussex Drive, Ottawa, ON K1A 0G2<br />Canada<br />Telephone: (343)203-4273<br />Fax: (613)943-0346<br />E-mail: <a href="mailto:[email protected]">[email protected]</a><br />
Distribution date: 17 February 2016 | Final date for Comment: 04 May 2025
Products Covered: Prescription status of medicinal ingredients for human use (ICS: 11.120; HS: 3004.90)
Regulation Type: Addendum to Regular Notification
Submit your email ID to receive notifications about upcoming courses and events
